Clinical Trials at Laura and Isaac Perlmutter Cancer Center at NYU Langone

As of August 2026, 62 paid clinical trials are recruiting at Laura and Isaac Perlmutter Cancer Center at NYU Langone in New York, New York. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 27, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

62 clinical trials at Laura and Isaac Perlmutter Cancer Center at NYU Langone

·Clear filters·

Get a weekly email when new trials open in New York, NY.

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

Sites in New York, Brooklyn +141 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting·Listed Apr 2017

Apply to this trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

for Central Nervous System Nongerminomatous Germ Cell Tumor

Sites in New York, Brooklyn +139 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT04684368·Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

for Gastric Adenocarcinoma

Sites in New York, Mineola +76 more locations

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT07001748·Phase 2, Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

for Childhood Medulloblastoma

Sites in New York, The Bronx +100 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 4 - 21

Code: NCT05382338·Phase 3·Recruiting·Listed May 2022

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

for Astrocytoma, IDH-Mutant, Grade 2

Sites in New York, Mineola +32 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06860594·Phase 1·Recruiting·Listed Mar 2025

Apply to this trial

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

for Anatomic Stage IV Breast Cancer AJCC v8

Sites in New York, Brooklyn +56 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500481·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

for Metastatic Malignant Solid Neoplasm

Sites in New York, Mineola +16 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05687110·Phase 1·Recruiting·Listed Jan 2023

Apply to this trial

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

for Embryonal Rhabdomyosarcoma

Sites in New York, The Bronx +162 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT05304585·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for Down Syndrome

Drug: Nivolumab

Sites in New York, Brooklyn +148 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 1 - 30

Code: NCT04546399·Phase 2·Recruiting·Listed Sep 2020

Apply to this trial

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

for Locally Advanced Pancreatic Adenocarcinoma

Drug: Peposertib

Sites in New York +27 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04172532·Phase 1, Phase 2·Recruiting·Listed Nov 2019

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

Sites in New York, Brooklyn +705 more locations

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021

Apply to this trial

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

for Recurrent Glioblastoma, IDH-Wildtype

Drug: Selinexor

Sites in New York +26 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05432804·Phase 1, Phase 2·Recruiting·Listed Jun 2022

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

Drug: Nivolumab

Sites in New York, Mineola +39 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting·Listed Jan 2019

Apply to this trial

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

for Advanced Malignant Solid Neoplasm

Drug: Peposertib

Sites in New York, Mineola +4 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05687136·Phase 1·Recruiting·Listed Jan 2023

Apply to this trial

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

for Anatomic Stage III Breast Cancer AJCC v8

Sites in New York, Mineola +4 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05422794·Phase 1·Recruiting·Listed Jun 2022

Apply to this trial

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

for Anatomic Stage IV Breast Cancer AJCC v8

Sites in New York +2 more locations

Sponsor: University of Washington

Sex: All·Age: 18+

Code: NCT06518057·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

for Acute Adult T-Cell Leukemia/Lymphoma

Sites in New York, Mineola +17 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04301076·Phase 1·Recruiting·Listed Mar 2020

Apply to this trial

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

for Clinical Stage III Cutaneous Melanoma AJCC v8

Sites in New York, Mineola +23 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05896839·Phase 1, Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

for Anatomic Stage I Breast Cancer AJCC v8

Sites in New York, Brooklyn +913 more locations

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05929768·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

for Chronic Lymphocytic Leukemia

Drug: Epcoritamab

Sites in New York +6 more locations

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07218510·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

for Recurrent B-Cell Non-Hodgkin Lymphoma

Drug: Nivolumab

Sites in New York, Mineola +6 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05272384·Phase 1·Recruiting·Listed Mar 2022

Apply to this trial

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for Endometrial Carcinoma

Sites in New York, The Bronx +329 more locations

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05256225·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial